Apixaban vs Dabigatran
## Overview
Apixaban (Xa inhibitor) and dabigatran (thrombin inhibitor) are both DOACs for AF and VTE, with very different target enzymes. Apixaban has the lowest GI bleeding rate and best tolerability; dabigatran has the most specific reversal agent.
## Mechanism of Action
Apixaban: direct Xa inhibitor. Dabigatran: direct thrombin inhibitor (prodrug etexilate → active dabigatran).
## Key Comparison Points
Dabigatran 150 mg BID (RE-LY trial) actually showed superiority to warfarin in stroke/SE prevention (not just non-inferiority) but with similar major bleeding. However, it had higher GI bleeding and more dyspepsia. Apixaban (ARISTOTLE) showed superiority in both stroke prevention and major bleeding vs warfarin.
Dabigatran's 80% renal clearance severely restricts its use in CKD. Apixaban's 27% renal clearance allows use down to CrCl 15 mL/min.
## Reversal Agents
Idarucizumab (Praxbind): specific, complete reversal of dabigatran within minutes — the fastest and most complete DOAC reversal available. Andexanet alfa: reverses Xa inhibitors (apixaban included) but is more expensive and requires infusion.
## Key Takeaways
- Apixaban: best overall bleeding profile, usable in CKD
- Dabigatran: fastest/most complete specific reversal (idarucizumab), highest renal dependence
- Dabigatran GI tolerability (dyspepsia) is a significant adherence issue
Veredicto
Apixaban is preferred over dabigatran for most patients due to superior tolerability (no dyspepsia), lower GI bleeding, and usability in CKD. Dabigatran may be considered when rapid, complete reversal with idarucizumab is a priority clinical consideration.